Direct Flow Reports Second-To-None Two-Year TAVR Survival Data
This article was originally published in The Gray Sheet
Executive Summary
Results from the CE mark trial of the company's transcatheter aortic valve as well as early data from the post-market registry so far support the company's claim that its device virtually eliminates aortic regurgitation.